HHS backs AstraZeneca COVID-19 vaccine candidate, could be ready by October

May 21, 2020 - 04:05 PM
Department of Health and Human Services (HHS) Seal

A collaboration between the Department of Health and Human Services and AstraZeneca is projected to make available 300 million doses of a COVID-19 vaccine, the first of which could be available as early as October, HHS today said.

The agreement is part of the White House’s Operation Warp Speed, a public-private effort to facilitate, at an unprecedented pace, the development, manufacturing and distribution of COVID-19 countermeasures. HHS says phase three clinical studies of AZD1222 are set to start in the summer. The Food and Drug Administration must still approve an emergency use authorization or licensure in order to make the vaccine available.

AZD1222 is the fourth vaccine candidate to receive HHS’ Biomedical Advanced Research and Development Authority support for late-state development and manufacturing. BARDA can provide up to $1.2 billion for vaccine manufacturing technology transfer, process development, scaled-up manufacturing and other development activities.

Related News Articles

Headline
CDC report finds COVID-19 vaccine for children reduced chances of ED, urgent care visits
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
AHA responds to FDA request for information on AI-enabled medical devices
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
Permanent recall issued for Baxter ventilation system
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
CDC data shows rise in flu, COVID-19 cases across states 
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
Recall issued for mislabeled potassium chloride
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
Study finds flu, COVID-19 infection temporarily raises risk of heart attack, stroke 
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…